Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187135 | 0.91 | KLK5 (0.49) | AKT1PPARAPPARGATMKMT2A | |
| SCHEMBL27603663 | 0.90 | CTSS (0.47) | PPARAPPARGKMT2AMEN1LMNA | |
| SCHEMBL26926114 | 0.87 | SYK (0.47) | AKT1PPARAPPARGATMKMT2A | |
| SCHEMBL23042932 | 0.87 | PPARA (0.49) | AKT1PPARAPPARGKMT2AACE | |
| SCHEMBL3556150 | 0.87 | ACE (0.56) | AKT1PPARAPPARGATMKMT2A | |
| SCHEMBL23040219 | 0.87 | SYK (0.47) | AKT1PPARAPPARGATMKMT2A | |
| SCHEMBL3559433 | 0.87 | ACE (0.56) | AKT1PPARAPPARGATMKMT2A | |
| SCHEMBL23040218 | 0.87 | SYK (0.47) | AKT1PPARAPPARGATMKMT2A | |
| SCHEMBL28750692 | 0.85 | CTSK (0.50) | PPARAPPARGACECTSSCTSL | |
| SCHEMBL28750690 | 0.85 | CTSK (0.50) | PPARAPPARGACECTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | AKT1 1709/4885PPARA 697/4885PPARG 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.